Alligator Bioscience Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Alligator Bioscience şirketinin kazançları yıllık ortalama -8.2% oranında azalırken, Biotechs sektörünün kazançları yıllık 7.7% oranında artan oldu. Gelirler yıllık ortalama 40.5% oranında artan oldu.

Anahtar bilgiler

-8.2%

Kazanç büyüme oranı

37.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.5%
Gelir büyüme oranı	40.5%
Özkaynak getirisi	n/a
Net Marj	-894.0%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Alligator Bioscience nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

LSE:0RK9 Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	28	-248	77
30 Jun 24	46	-234	78
31 Mar 24	56	-249	82
31 Dec 23	59	-249	79
30 Sep 23	68	-232	76
30 Jun 23	53	-231	75
31 Mar 23	40	-213	72
31 Dec 22	36	-193	69
30 Sep 22	21	-177	65
30 Jun 22	20	-163	63
31 Mar 22	18	-152	59
31 Dec 21	13	-142	57
30 Sep 21	8	-139	54
30 Jun 21	5	-133	51
31 Mar 21	6	-133	53
31 Dec 20	6	-143	56
30 Sep 20	5	-169	59
30 Jun 20	9	-194	62
31 Mar 20	4	-209	62
31 Dec 19	4	-210	61
30 Sep 19	30	-181	60
30 Jun 19	26	-164	58
31 Mar 19	26	-152	55
31 Dec 18	27	-150	52
30 Sep 18	53	-107	54
30 Jun 18	54	-93	51
31 Mar 18	55	-86	48
31 Dec 17	57	-64	44
30 Sep 17	12	-96	40
30 Jun 17	15	-77	37
31 Mar 17	18	-91	35
31 Dec 16	59	-48	33
30 Sep 16	55	-68	31
31 Dec 15	292	207	32
31 Dec 14	1	-77	31

Kaliteli Kazançlar: 0RK9 şu anda kârlı değil.

Büyüyen Kar Marjı: 0RK9 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0RK9 kârlı değildir ve zararlar son 5 yılda yılda 8.2% oranında artmıştır.

Büyüme Hızlandırma: 0RK9 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 0RK9 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 0RK9 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Alligator Bioscience Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.066 loss per share (vs kr0.19 loss in 2Q 2023)

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.28 loss per share (vs kr0.20 loss in 1Q 2022)

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Recent updates

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.083 loss in 3Q 2023)

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Second quarter 2024 earnings released: kr0.066 loss per share (vs kr0.19 loss in 2Q 2023)

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

High number of new directors

High number of new directors

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

High number of new and inexperienced directors

High number of new and inexperienced directors

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

High number of new and inexperienced directors

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

High number of new directors

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

High number of new directors

First quarter 2023 earnings released: kr0.28 loss per share (vs kr0.20 loss in 1Q 2022)

High number of new directors

High number of new directors

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

High number of new directors

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

High number of new directors

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Less than half of directors are independent

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin